CAESAREA, Israel and
NEW YORK, Oct. 22, 2019 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a
leading, global digital therapeutics company, has appointed Dr.
Abigail Hirsch to its Advisory Board
where she will help guide commercial and Business-to-Business (B2B)
efforts.
Dr. Hirsch has many years of experience utilizing clinical
psychology, data analytics and educational design to create
innovative healthcare technology that helps people lead healthier,
more fulfilling lives.
Prior to joining Dario, Dr. Hirsch served as Chief Clinical
Officer at a behavioral health company called myStrength, helping
lead the company from inception through its acquisition by Livongo
Health, Inc. in the first quarter of 2019. She holds a Ph.D. in
Clinical Psychology from the University of
Massachusetts.
"Dr. Hirsch has an impressive track record of successfully
advancing the development of digital therapeutic programs in the
health tech industry. She brings her extensive experience to
DarioHealth's digital chronic condition management platform. This
is particularly relevant because of the behavioral components in
our platform which integrate data collection and analytics with
coaching and digital lifestyle management. We expect Dario will
benefit greatly from her unique perspective and guidance as she
helps shape our position in the field of chronic condition
management," said Erez Raphael,
CEO.
Dr. Hirsch added, "I love Dario's solution and am very excited
to be joining their team. Dario's unique digital therapeutics
platform is distinguished by its client-centered approach. This
facet of the technology has proven successful in engaging users to
better manage their health. I look forward to working closely with
the Dario team as we further penetrate the B2B market with
solutions that advance the management of chronic conditions while
positively impacting patients, providers and payers."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading,
global digital therapeutics company revolutionizing the way
people with chronic conditions manage their health. By delivering
evidence-based interventions that are driven by data, high-quality
software and coaching, we empower individuals to make healthy
adjustments to their daily lifestyle choices to improve their
overall health. Our cross-functional team operates at the
intersection of life sciences, behavioral science and software
technology to deliver highly engaging therapeutic interventions.
Dario is one of the highest-rated diabetes solutions in the market,
and its user-centric MyDario™ mobile app is loved by tens of
thousands of consumers around the globe. DarioHealth is rapidly
moving into new chronic conditions and geographic markets, using a
performance-based approach to improve the health of users managing
chronic disease. To learn more about DarioHealth and its digital
health solutions, please go
to: http://mydario.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company describes
its expectation that it will benefit greatly from Dr. Hirsch's
unique perspective and guidance as she helps shape its position in
the field of chronic condition management and that Dr. Hirsch will
work closely with the Dario team as it further penetrates the B2B
market with solutions that advance the management of chronic
conditions while positively impacting patients, providers and
payers, it is using forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact:
Claudia
Levi
Content & Communications Manager
claudia@mydario.com
+1 347-767-4220
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-appoints-digital-therapeutics-pioneer-dr-abigail-hirsch-to-its-advisory-board-to-support-commercial-strategy-and-execution-300942898.html
SOURCE DarioHealth Corp.